Performance Evaluation of Montelukast Pediatric Formulations: Part II — a PBPK Modelling Approach
![graphical abstract of Performance Evaluation of Montelukast Pediatric Formulations: Part II — a PBPK Modelling Approach](https://www.pharmaexcipients.com/wp-content/uploads/2022/01/Performance-Evaluation-of-Montelukast-Pediatric-Formulations_Part-II-—-a-PBPK-Modelling-Approach.png)
This study aimed to build a physiologically based pharmacokinetic (PBPK) model coupled with age-appropriate in vitro dissolution data to describe drug performance in adults and pediatric patients. Montelukast sodium was chosen as a model drug. Two case studies were investigated: case study 1 focused on the description of formulation performance from adults to children; case study 2 focused on the description of the impact of medicine co-administration with vehicles on drug exposure in infants.
The PBPK model for adults and pediatric patients was developed in Simcyp® v18.2 informed by age-appropriate in vitro dissolution results obtained in a previous study. Oral administration of montelukast was simulated with the ADAM™ model. For case study 1, the developed PBPK model accurately described montelukast exposure in adults and children populations after the administration of montelukast chewable tablets. Two-stage dissolution testing in simulated fasted gastric to intestinal conditions resulted in the best description of in vivo drug performance in adults and children.
For case study 2, a good description of in vivo drug performance in infants after medicine co-administration with vehicles was achieved by incorporating in vitro drug dissolution (under simulated fasted gastric to fed intestinal conditions) into a fed state PBPK model with consideration of the in vivo dosing conditions (mixing of formulation with applesauce or formula). The case studies presented demonstrate how a PBPK absorption modelling strategy can facilitate the description of drug performance in the pediatric population to support decision-making and biopharmaceutics understanding during pediatric drug development.
Download the full article as a PDF here or read it here
Article information: Guimarães, M., Vertzoni, M. & Fotaki, N. Performance Evaluation of Montelukast Pediatric Formulations: Part II — a PBPK Modelling Approach. AAPS J 24, 27 (2022). https://doi.org/10.1208/s12248-021-00662-1